Angioplasty of arteries of lower extremities for peripheral artery disease

Table of content

1.    Introduction and summary
2.    Executive summary table
2.1.    Percutaneous transluminal angioplasty with plain balloon
2.2.    Percutaneous transluminal angioplasty with drug-eluting balloon
2.3.    Percutaneous transluminal angioplasty with insertion of bare metal stent
2.4.    Percutaneous transluminal angioplasty with insertion of drug-eluting stent
3.    Contents
4.    Methodology
5.    Reimbursement analysis in Austria
5.1.    Overview of the reimbursement system
5.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
5.2.1.    Procedure coding
5.2.2.    Diagnosis coding
5.2.3.    Payment mechanism and reimbursement tariffs
5.2.4.    Health technology assessment by LBI-HTA
5.2.4.1.    Percutaneous transluminal angioplasty with drug-eluting stent
5.2.4.2.    Percutaneous transluminal angioplasty with drug-eluting balloon 
6.    Reimbursement analysis in Belgium
6.1.    Overview of the reimbursement system
6.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
6.2.1.    Procedure coding 
6.2.2.    Material coding
6.2.3.    Payment mechanism and reimbursement tariffs
6.2.4.    Brand-specific reimbursement for drug-eluting stents and drug-coated balloons
6.2.5.    Policy considerations
6.2.5.1.    Reimbursement framework for percutaneous transluminal angioplasty with insertion of drug-eluting stent determined by INAMI
6.2.5.2.    Reimbursement framework for percutaneous transluminal angioplasty with drug-eluting balloon determined by INAMI
6.2.5.3.    Health technology assessment by Belgian Health Care Knowledge Centre
7.    Reimbursement analysis in Denmark
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
7.2.1.    Procedure coding 
7.2.2.    Diagnosis coding
7.2.3.    Payment mechanism and reimbursement tariffs
8.    Reimbursement analysis in England
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
8.2.1.    Procedure coding 
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.4.    Policy considerations 
8.2.4.1.    National commissioning of percutaneous transluminal angioplasty with or without stenting by NHS England 
8.2.4.2.    Health technology assessment of percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease by NICE
8.2.4.3.    Clinical guideline for diagnosis and management of peripheral arterial disease by NICE
9.    Reimbursement analysis in France
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Brand-specific reimbursement 
9.2.5.    Policy considerations
9.2.5.1.    Drug-eluting balloons
9.2.5.2.    Bare metal stents
9.2.5.3.    Self-expanding drug-eluting stents
10.    Reimbursement analysis in Germany
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs in hospital setting
10.2.4.    Payment mechanism and reimbursement tariffs in day case
10.2.5.    Policy considerations
11.    Reimbursement analysis in Italy
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs at national level
11.2.4.    Payment mechanism and reimbursement tariffs at regional level
12.    Reimbursement analysis in the Netherlands
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
12.2.1.    Procedure coding
12.2.1.1.    Procedure coding for intervention performed by surgeon
12.2.1.2.    Procedure coding for interventions performed by radiologist 
12.2.2.    Material coding
12.2.3.    Diagnosis coding
12.2.4.    Payment mechanism and reimbursement tariffs
12.2.4.1.    Payment mechanism and reimbursement tariffs for interventions performed by surgeon
12.2.4.2.    Payment mechanism and reimbursement tariffs for interventions performed by radiologist
12.2.5.    Policy considerations
12.2.6.    Health technology assessment by National Healthcare Institute
13.    Reimbursement analysis in Norway
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
13.2.1.    Procedure coding 
13.2.2.    Diagnosis coding
13.2.3.    Payment mechanism and reimbursement tariffs in hospital setting
13.2.4.    Payment mechanism and reimbursement tariffs in day case
13.2.5.    Policy considerations
13.2.5.1.    Assessment within national framework of managed introduction of innovations 
14.    Reimbursement analysis in Sweden
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs in hospital setting
14.2.4.    Payment mechanism and reimbursement tariffs in day case
14.2.5.    Policy considerations 
14.2.5.1.    Swedish Drug-elution Trial in Peripheral Arterial Disease trial (SWEDEPAD)
15.    Reimbursement analysis in Switzerland
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for percutaneous transluminal angioplasty with or without stenting for peripheral arterial disease technologies
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs in hospital setting
15.2.4.    Payment mechanism and reimbursement tariffs in day case
15.2.5.    Policy considerations 
16.    Disclaimer